Governments around the world have focused on issues of sustainability, innovations and priority setting within their health systems. Tension exists between governments' desire to increase biotechnology innovation and the need to address health system sustainability. This commentary will: (1) review government initiatives in biotechnology in health innovation; (2) discuss how innovation, specifically biopharmaceuticals, challenges health system sustainability; and (3) explore how the tension between innovation and sustainability can be addressed using fairness and legitimacy. It is evident that a uni-jurisdictional approach may not be optimal in promoting innovation while ensuring a sustainable health system. Harmonization of biotechnology policies across the federal, provincial, and territorial governments will ensure consistent policies across all branches in order to circumvent the possibility of one governmental branch refusing to reimburse the very innovations other branches are promoting. © 2008 Elsevier Ireland Ltd. All rights reserved.
CITATION STYLE
Rosenberg-Yunger, Z. R. S., Daar, A. S., Singer, P. A., & Martin, D. K. (2008). Healthcare sustainability and the challenges of innovation to biopharmaceuticals in Canada. Health Policy, 87(3), 359–368. https://doi.org/10.1016/j.healthpol.2008.02.004
Mendeley helps you to discover research relevant for your work.